CDEK by Data4ThePeople
IndicationsMechanismsTrialsFDA ApprovalsAbout
Sign in Sign up
IndicationsMechanismsTrialsFDA ApprovalsAbout
← All indications

Liposarcoma, Myxoid

A liposarcoma containing round mesenchymal cells and a myxoid extracellular matrix in stroma.

Drugs by status

Phase 2 trials (12)

  • urea
  • brostallicin
  • doxorubicin
  • palbociclib
  • mirdametinib
  • ifosfamide
  • sirolimus
  • cyclophosphamide
  • trabectedin
  • pioglitazone
  • seclidemstat
  • Afamitresgene autoleucel

Phase 1 trials (4)

  • pembrolizumab
  • tcr-t cells
  • btx-a51
  • pepticrad-1

Other trials (2)

  • tazemetostat
  • interferon gamma-1b

Organizations

Organization Involved with Phase 2 Indications (20)

  • Adaptimmune
  • Daiichi Sankyo
  • Genentech
  • CTI BioPharma
  • Immune Design
  • PharmaMar
  • Systems Medicine LLC
  • National Cancer Institute (NCI)
  • Centre Leon Berard
  • Cornell University
  • Georgetown University
  • University of Washington
  • Grupo Espanol de Investigacion en Sarcomas
  • Italian Sarcoma Group
  • Leiden University
  • Cancer Immunotherapy Trials Network
  • Janssen Pharmaceutica NV
  • University of Texas at Houston
  • Maria Sklodowska Curie Children's Hospital
  • Johnson and Johnson

Organization Involved with Phase 1 Indications (2)

  • Incyte
  • University of Pennsylvania

CDEK

The Clinical Drug Experience Knowledgebase — tracking drugs, sponsoring organizations, and clinical trials from first-in-human testing through approval.

Browse

  • Drugs
  • Organizations
  • Trials

About

  • About CDEK
  • Glossary

Built and maintained by Data4ThePeople.

YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED "AS IS", WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.